AR072477A1 - Formulacion farmaceutica de eprosartan. uso. - Google Patents
Formulacion farmaceutica de eprosartan. uso.Info
- Publication number
- AR072477A1 AR072477A1 ARP090102539A ARP090102539A AR072477A1 AR 072477 A1 AR072477 A1 AR 072477A1 AR P090102539 A ARP090102539 A AR P090102539A AR P090102539 A ARP090102539 A AR P090102539A AR 072477 A1 AR072477 A1 AR 072477A1
- Authority
- AR
- Argentina
- Prior art keywords
- eprosartan
- dose
- acid
- pharmaceutical formulation
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método de tratamiento de un trastorno modulado mediante el bloqueo de los receptores de angiotensina II (AII), y particularmente seleccionados del grupo que consiste de hipertension, falla cardiaca congestiva, falla renal, y combinaciones de los mismos, administrando a un sujeto en necesidad del mismo una dosis efectiva de un compuesto de eprosartan. Con referencia a la Dosis Diaria Efectiva Recomendada de 600 mg, calculada en base a eprosartan administrada en forma de mesilato de eprosartan, ahora se ha hallado que puede ser administrada una dosis menor de eprosartan cuando el compuesto de eprosartan es eprosartan ácido. Esta dosis está en el rango de desde 410 a 490 mg, lo más preferiblemente aproximadamente 450 mg. Reivindicacion 1: Una formulacion farmacéutica de eprosartan que comprende 410-490 mg, preferiblemente 420-480 mg, de eprosartan ácido. Reivindicacion 9: Una formulacion farmacéutica de acuerdo con la reivindicacion 8, que comprende gránulos mezclados en seco de monohidrato de lactosa 200M y celulosa microcristalina, más preferiblemente celulosa microcristalina silicificada, almidon y N-vinil-2-pirrolidona entrecruzada. Reivindicacion 10: Una formulacion farmacéutica de acuerdo con una cualquiera de las reivindicaciones 1 a 9, que comprende un compuesto diurético, preferiblemente hidroclorotiazida, como ingrediente activo adicional. Reivindicacion 12: El uso de eprosartan ácido con el proposito de proveer un producto de droga que es bioequivalente con un producto de droga de referencia que comprende mesilato de eprosartan cristalino como sustancia activa, en donde la dosis bioequivalente de eprosartan ácido es menor que la dosis de referencia de mesilato de eprosartan, calculada en base a eprosartan ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160211 | 2008-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072477A1 true AR072477A1 (es) | 2010-09-01 |
Family
ID=39731507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102539A AR072477A1 (es) | 2008-07-11 | 2009-07-07 | Formulacion farmaceutica de eprosartan. uso. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20100010062A1 (es) |
| EP (1) | EP2317987B1 (es) |
| JP (1) | JP2011527314A (es) |
| KR (1) | KR20110031226A (es) |
| CN (1) | CN102088961A (es) |
| AR (1) | AR072477A1 (es) |
| AU (1) | AU2009268044A1 (es) |
| BR (1) | BRPI0915455A2 (es) |
| CA (1) | CA2730008A1 (es) |
| CO (1) | CO6331424A2 (es) |
| DO (1) | DOP2011000011A (es) |
| EA (1) | EA201170182A1 (es) |
| EC (1) | ECSP10010701A (es) |
| IL (1) | IL210001A0 (es) |
| MX (1) | MX2011000349A (es) |
| NZ (1) | NZ589904A (es) |
| PE (1) | PE20110412A1 (es) |
| TW (1) | TW201006826A (es) |
| UA (1) | UA100434C2 (es) |
| WO (1) | WO2010003996A1 (es) |
| ZA (1) | ZA201100223B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5910311B2 (ja) * | 2012-05-23 | 2016-04-27 | ニプロ株式会社 | 医薬錠剤およびその製造方法 |
| CN102755322B (zh) * | 2012-07-24 | 2013-12-11 | 兆科药业（广州）有限公司 | 一种乐卡地平和阿托伐他汀复方制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG52330A1 (en) * | 1989-06-14 | 1998-09-28 | Smithkline Beecham Corp | Imidazolyl-alkenoic acids |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| AU750611B2 (en) * | 1997-11-17 | 2002-07-25 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| WO2000004862A2 (en) * | 1998-07-20 | 2000-02-03 | Smithkline Beecham Corporation | Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| JP2007512265A (ja) * | 2003-12-01 | 2007-05-17 | ライフサイクル ファーマ アクティーゼルスカブ | レルカニジピンを含む医薬組成物 |
| EP1734953A4 (en) * | 2004-03-02 | 2008-08-20 | Abeille Pharmaceuticals Inc | CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS |
| FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
| FR2886150B1 (fr) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
| EP1948136A1 (en) * | 2005-11-07 | 2008-07-30 | King Pharmaceuticals Research and Development, Inc. | Compositions of stabilized ramipril in combination with another active agent |
-
2009
- 2009-07-07 AR ARP090102539A patent/AR072477A1/es not_active Application Discontinuation
- 2009-07-08 TW TW098123060A patent/TW201006826A/zh unknown
- 2009-07-09 NZ NZ589904A patent/NZ589904A/xx not_active IP Right Cessation
- 2009-07-09 JP JP2011517158A patent/JP2011527314A/ja active Pending
- 2009-07-09 PE PE2011000022A patent/PE20110412A1/es not_active Application Discontinuation
- 2009-07-09 MX MX2011000349A patent/MX2011000349A/es active IP Right Grant
- 2009-07-09 EP EP09780358.9A patent/EP2317987B1/en active Active
- 2009-07-09 CN CN200980127192XA patent/CN102088961A/zh active Pending
- 2009-07-09 WO PCT/EP2009/058724 patent/WO2010003996A1/en active Application Filing
- 2009-07-09 BR BRPI0915455A patent/BRPI0915455A2/pt not_active IP Right Cessation
- 2009-07-09 US US12/500,425 patent/US20100010062A1/en not_active Abandoned
- 2009-07-09 AU AU2009268044A patent/AU2009268044A1/en not_active Abandoned
- 2009-07-09 UA UAA201101523A patent/UA100434C2/ru unknown
- 2009-07-09 EA EA201170182A patent/EA201170182A1/ru unknown
- 2009-07-09 CA CA2730008A patent/CA2730008A1/en not_active Abandoned
- 2009-07-09 KR KR1020117003089A patent/KR20110031226A/ko not_active Application Discontinuation
-
2010
- 2010-12-15 IL IL210001A patent/IL210001A0/en unknown
- 2010-12-21 EC EC2010010701A patent/ECSP10010701A/es unknown
-
2011
- 2011-01-07 DO DO2011000011A patent/DOP2011000011A/es unknown
- 2011-01-07 ZA ZA2011/00223A patent/ZA201100223B/en unknown
- 2011-01-14 CO CO11003597A patent/CO6331424A2/es not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/565,872 patent/US20120302555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2011000011A (es) | 2011-01-31 |
| CO6331424A2 (es) | 2011-10-20 |
| CN102088961A (zh) | 2011-06-08 |
| UA100434C2 (en) | 2012-12-25 |
| IL210001A0 (en) | 2011-02-28 |
| EP2317987A1 (en) | 2011-05-11 |
| US20120302555A1 (en) | 2012-11-29 |
| US20100010062A1 (en) | 2010-01-14 |
| NZ589904A (en) | 2012-08-31 |
| PE20110412A1 (es) | 2011-07-04 |
| MX2011000349A (es) | 2011-02-22 |
| ECSP10010701A (es) | 2011-01-31 |
| AU2009268044A1 (en) | 2010-01-14 |
| EA201170182A1 (ru) | 2011-08-30 |
| TW201006826A (en) | 2010-02-16 |
| WO2010003996A1 (en) | 2010-01-14 |
| ZA201100223B (en) | 2011-10-26 |
| JP2011527314A (ja) | 2011-10-27 |
| BRPI0915455A2 (pt) | 2017-06-27 |
| KR20110031226A (ko) | 2011-03-24 |
| CA2730008A1 (en) | 2010-01-14 |
| EP2317987B1 (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109719T1 (el) | Σκευασμα 1-[(3-υδροξυ-αδαμαντ-1-υλαμινο)-ακετυλο]-πυρρολιδινο-2-(s)-καρβονιτριλιου τροποποιημενης απελευθερωσης | |
| JP2022130630A (ja) | ベンダムスチンの製剤 | |
| RU2010123027A (ru) | Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep) | |
| AR087210A2 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| RU2009110452A (ru) | Галеновые составы алискирена | |
| CA2614085A1 (en) | Pharmaceutical dosage form based on an osmotic active ingredient release system comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin ii antagonist | |
| PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| TR200604349A2 (tr) | Aripiprazol içeren farmasötik bileşimler | |
| WO2014027334A2 (es) | Composicion farmacéutica oral en forma de microesferas y proceso de elaboración | |
| EA201270087A1 (ru) | Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение | |
| JP6231959B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| MX2019008813A (es) | Composiciones para el tratamiento de la hipertension. | |
| Lam | Azilsartan: a newly approved angiotensin II receptor blocker | |
| HRP20120134T1 (hr) | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem | |
| CA2949154A1 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| AR072477A1 (es) | Formulacion farmaceutica de eprosartan. uso. | |
| EA201100916A1 (ru) | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета | |
| MY152022A (en) | A novel benzoxazine benzimidazole derivatives, a pharmaceutical composition comprising the same, and a use thereof | |
| RU2009135981A (ru) | Фармацевтические композиции, содержащие ирбесартан | |
| Israili et al. | Direct renin inhibitors as antihypertensive agents | |
| RU2006145311A (ru) | Твердая фармацевтическая композиция | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| CA3008701A1 (en) | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |